scholarly journals Healthcare-Associated Mycobacterium bovis–Bacille Calmette-Guérin (BCG) Infection in Cancer Patients Without Prior BCG Instillation

2017 ◽  
Vol 65 (7) ◽  
pp. 1136-1143 ◽  
Author(s):  
Yolanda Meije ◽  
Joaquín Martínez-Montauti ◽  
Joan A Caylà ◽  
Jose Loureiro ◽  
Lucía Ortega ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Mycobacterium Bovis ◽  
Bacille Calmette Guerin ◽  
Healthcare Associated ◽  
Bcg Instillation

scholarly journals Identification of N6,N6-Dimethyladenosine in Transfer RNA from Mycobacterium bovis Bacille Calmette-Guérin

Molecules ◽  
2011 ◽  
Vol 16 (6) ◽  
pp. 5168-5181 ◽  
Author(s):  
Clement Chan ◽  
Yok Hian Chionh ◽  
Chia-Hua Ho ◽  
Kok Seong Lim ◽  
I. Ramesh Babu ◽  
...  
Keyword(s):  
Mycobacterium Bovis ◽  
Transfer Rna ◽  
Bacille Calmette Guerin

100 years of Mycobacterium bovis bacille Calmette-Guérin

2021 ◽  
Author(s):  
Christoph Lange ◽  
Peter Aaby ◽  
Marcel A Behr ◽  
Peter R Donald ◽  
Stefan H E Kaufmann ◽  
...  
Keyword(s):  
Mycobacterium Bovis ◽  
Bacille Calmette Guerin

scholarly journals After 100 Years of BCG Immunization against Tuberculosis, What Is New and Still Outstanding for This Vaccine?

Vaccines ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 57
Author(s):  
Mario Alberto Flores-Valdez
Keyword(s):  
Mycobacterium Bovis ◽  
Human Beings ◽  
Bacille Calmette Guerin ◽  
The World ◽  
Vaccination Campaigns

In 2021, most of the world was reasonably still concerned about the COVID-19 pandemic, how cases were up and down in different countries, how the vaccination campaigns were ongoing, and most people were familiar with the speed with which vaccines against SARS-Co-V2 were developed, analyzed, and started to be applied in an attempt to curb the pandemic. Because of this, it may have somehow passed relatively inadvertently for people outside of the field that the vaccine used to control tuberculosis (TB), Mycobacterium bovis Bacille Calmette-Guérin (BCG), was first applied to humans a century ago. Over these years, BCG has been the vaccine applied to most human beings in the world, despite its known lack of efficacy to fully prevent respiratory TB. Several strategies have been employed in the last 20 years to produce a novel vaccine that would replace, or boost, immunity and protection elicited by BCG. In this work, to avoid potential redundancies with recently published reviews, I only aim to present my current thoughts about some of the latest findings and outstanding questions that I consider worth investigating to help develop a replacement or modified BCG in order to successfully fight TB, based on BCG itself.

scholarly journals Nicotinamide Limits Replication of Mycobacterium tuberculosis and Bacille Calmette-Guérin Within Macrophages

2019 ◽  
Vol 221 (6) ◽  
pp. 989-999
Author(s):  
Jason D Simmons ◽  
Glenna J Peterson ◽  
Monica Campo ◽  
Jenny Lohmiller ◽  
Shawn J Skerrett ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Nicotinic Acid ◽  
Mycobacterium Bovis ◽  
Related Compound ◽  
Antimicrobial Properties ◽  
Broth Culture ◽  
Wild Type ◽  
Bacille Calmette Guerin ◽  
Macrophage Function ◽  
Modest Activity

Abstract Novel antimicrobials for treatment of Mycobacterium tuberculosis are needed. We hypothesized that nicotinamide (NAM) and nicotinic acid (NA) modulate macrophage function to restrict M. tuberculosis replication in addition to their direct antimicrobial properties. Both compounds had modest activity in 7H9 broth, but only NAM inhibited replication in macrophages. Surprisingly, in macrophages NAM and the related compound pyrazinamide restricted growth of bacille Calmette-Guérin but not wild-type Mycobacterium bovis, which both lack a functional nicotinamidase/pyrazinamidase (PncA) rendering each strain resistant to these drugs in broth culture. Interestingly, NAM was not active in macrophages infected with a virulent M. tuberculosis mutant encoding a deletion in pncA. We conclude that the differential activity of NAM and nicotinic acid on infected macrophages suggests host-specific NAM targets rather than PncA-dependent direct antimicrobial properties. These activities are sufficient to restrict attenuated BCG, but not virulent wild-type M. bovis or M. tuberculosis.

scholarly journals Mycobacterium bovis Osteitis Following Immunization with Bacille Calmette-Guérin (BCG) in Korea

2019 ◽  
Vol 34 (1) ◽  
Author(s):  
Youn Young Choi ◽  
Mi Seon Han ◽  
Hoan Jong Lee ◽  
Ki Wook Yun ◽  
Chang Ho Shin ◽  
...  
Keyword(s):  
Mycobacterium Bovis ◽  
Bacille Calmette Guerin

scholarly journals Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer

2012 ◽  
Vol 1 (3) ◽  
Author(s):  
Vincent Fradet ◽  
Christiane Gaudreau ◽  
Paul Perrotte ◽  
Jean Côté ◽  
Jean-Marie Paquin
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Mycobacterium Bovis ◽  
Superficial Bladder Cancer ◽  
Granulomatous Hepatitis ◽  
Bacille Calmette Guerin ◽  
Systemic Complications ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Management Alternatives

Intravesical bacille Calmette-Guérin (BCG) therapy is the most effective treatmentfor high-risk superficial bladder cancer. Severe systemic complications are rare, but may occur in approximately 1% of cases. We report a severe complicationof intravesical BCG: a disseminated Mycobacterium bovis infectionwith biopsy-proven granulomatous hepatitis in a patient with bladder cancer. We also elaborate on the different management alternatives.

Sign in / Sign up

Export Citation Format

Share Document